Drug facts
Semaglutide and obstructive sleep apnea
Quick answer
No. “Sleep apnea” appears zero times in the full published semaglutide label. That indication belongs to tirzepatide, which is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Semaglutide’s own approvals beyond weight are cardiovascular risk reduction and MASH.
The short answer1
We searched the whole label. The phrase does not occur, in the indications or anywhere else. This is one of the clearest points of difference between the two molecules, and it runs the opposite way from most comparisons on this site.
What it is approved for instead2
- Cardiovascular risk reduction — reducing the risk of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight.
- Weight reduction and long-term maintenance, in adults and in patients aged 12 and older with obesity, or adults with overweight and a weight-related condition.
- Noncirrhotic MASH with moderate to advanced liver fibrosis, under accelerated approval — which means continued approval may depend on a confirmatory trial.
Why the confusion2
Because weight loss improves sleep apnea regardless of how it is achieved, so a drug that produces weight loss will help some people with it. That is not the same as being approved for it: an approval means a trial measured that condition as an endpoint and a regulator reviewed the result. For sleep apnea, that trial was run with the other molecule — see how the two compare.
What this page is not
It is not a reason to choose one drug over the other; that is a clinical decision. It reports which conditions each label actually covers.